Samsung Biologics Co.,Ltd. Statistics

Total Valuation

Samsung Biologics Co.,Ltd. has a market cap or net worth of KRW 66.90 trillion. The enterprise value is 66.89 trillion.

Market Cap	66.90T
Enterprise Value	66.89T

Important Dates

The next estimated earnings date is Friday, January 24, 2025.

Earnings Date	Jan 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Samsung Biologics Co.,Ltd. has 71.17 million shares outstanding. The number of shares has decreased by -0.01% in one year.

Current Share Class	n/a
Shares Outstanding	71.17M
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	14.41%
Float	18.07M

Valuation Ratios

The trailing PE ratio is 63.57 and the forward PE ratio is 61.59. Samsung Biologics Co.,Ltd.'s PEG ratio is 3.21.

PE Ratio	63.57
Forward PE	61.59
PS Ratio	15.33
PB Ratio	6.32
P/TBV Ratio	8.76
P/FCF Ratio	60.88
P/OCF Ratio	n/a
PEG Ratio	3.21

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 34.57, with an EV/FCF ratio of 60.86.

EV / Earnings	63.55
EV / Sales	15.33
EV / EBITDA	34.57
EV / EBIT	49.75
EV / FCF	60.86

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.09.

Current Ratio	1.35
Quick Ratio	0.28
Debt / Equity	0.09
Debt / EBITDA	0.50
Debt / FCF	0.88
Interest Coverage	29.57

Financial Efficiency

Return on equity (ROE) is 10.45% and return on invested capital (ROIC) is 7.21%.

Return on Equity (ROE)	10.45%
Return on Assets (ROA)	5.27%
Return on Capital (ROIC)	7.21%
Revenue Per Employee	919.98M
Profits Per Employee	221.86M
Employee Count	4,744
Asset Turnover	0.27
Inventory Turnover	0.85

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.14% in the last 52 weeks. The beta is 0.39, so Samsung Biologics Co.,Ltd.'s price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+19.14%
50-Day Moving Average	974,000.00
200-Day Moving Average	891,080.00
Relative Strength Index (RSI)	44.80
Average Volume (20 Days)	70,462

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Samsung Biologics Co.,Ltd. had revenue of KRW 4.36 trillion and earned 1.05 trillion in profits. Earnings per share was 14,787.79.

Revenue	4.36T
Gross Profit	2.14T
Operating Income	1.34T
Pretax Income	1.35T
Net Income	1.05T
EBITDA	1.93T
EBIT	1.34T
Earnings Per Share (EPS)	14,787.79

Full Income Statement

Balance Sheet

The company has 988.11 billion in cash and 969.81 billion in debt, giving a net cash position of 18.30 billion or 257.06 per share.

Cash & Cash Equivalents	988.11B
Total Debt	969.81B
Net Cash	18.30B
Net Cash Per Share	257.06
Equity (Book Value)	10.59T
Book Value Per Share	148,812.06
Working Capital	1.25T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.10 trillion and capital expenditures -1,003.61 billion, giving a free cash flow of 1.10 trillion.

Operating Cash Flow	2.10T
Capital Expenditures	-1,003.61B
Free Cash Flow	1.10T
FCF Per Share	15,440.33

Full Cash Flow Statement

Margins

Gross margin is 49.10%, with operating and profit margins of 30.80% and 24.12%.

Gross Margin	49.10%
Operating Margin	30.80%
Pretax Margin	30.97%
Profit Margin	24.12%
EBITDA Margin	44.33%
EBIT Margin	30.80%
FCF Margin	25.18%

Dividends & Yields

Samsung Biologics Co.,Ltd. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.01%
Shareholder Yield	0.01%
Earnings Yield	1.57%
FCF Yield	1.64%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Samsung Biologics Co.,Ltd. has an Altman Z-Score of 7.39.

Altman Z-Score	7.39
Piotroski F-Score	n/a